Reviva Pharmaceuticals Holdings (RVPH) Other Non Operating Income (2021 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Other Non Operating Income of $809.0 for Q4 2025, up 111.94% sequentially from -$6774.0 in Q3 2025, and up 100.12% YoY from $404.26 in Q4 2024.
Reviva Pharmaceuticals Holdings (RVPH) Other Non Operating Income (2021 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Other Non Operating Income for 5 years, with the latest figure at $809.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 100.12% year-over-year to $809.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $5161.0 (up 100.99% YoY) and the FY2025 annual result came in at -$32960.0, down 158.51% from the prior year.
- Other Non Operating Income advanced to $809.0 in Q4 2025 per RVPH's latest filing, from -$6774.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $923480.0 in Q1 2021 and troughed at -$672438.0 in Q4 2024.
- A 5-year average of $73820.5 and a median of $17532.0 in 2023 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 1054168.42% in 2024, down 3935.49% in 2024.
- Over 5 years, Other Non Operating Income stood at $278156.0 in 2021, then plunged by 91.91% to $22515.0 in 2022, then decreased by 22.13% to $17532.0 in 2023, then plunged by 3935.49% to -$672438.0 in 2024, then surged by 100.12% to $809.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $809.0, -$6774.0, and $11126.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,040.00 |
| Mar 31, 2026 | -3,390.00 |
| Dec 31, 2025 | 809.00 |
| Sep 30, 2025 | -6,774.00 |
| Jun 30, 2025 | 11,126.00 |
| Mar 31, 2025 | -25,145.00 |
| Dec 31, 2024 | -672,438.00 |
| Sep 30, 2024 | -23,687.00 |
| Jun 30, 2024 | 200,273.00 |
| Mar 31, 2024 | -129,894.00 |
| Dec 31, 2023 | 17,532.00 |
| Sep 30, 2023 | 139,079.00 |
| Jun 30, 2023 | -19.00 |
| Mar 31, 2023 | 11,126.00 |
| Dec 31, 2022 | 22,515.00 |
| Jun 30, 2022 | 178,021.00 |
| Mar 31, 2022 | 89,010.00 |
| Dec 13, 2021 | 278,156.00 |
| Sep 30, 2021 | 200,273.00 |
| Jun 30, 2021 | 189,146.00 |